Furthermore, a discordant receptor status between the primary tumor and these cells with regard to the human epidermal growth factor receptor 2 (HER2) and the estrogen receptor (ER) has been demonstrated which might lead to uneffective trastuzumab and/or antihormonal treatment14, 15, 16. Here, ERBB2 is linked to neoplasm.